The serum standard, 89-SF, and 5 calibration sera showed specificity in the detection of the IgG for the 7 PnPS antigens. overall performance using the standardized WHO ELISA for the evaluation of serotype-specific anti-pneumococcal IgG antibodies; the WHO ELISA can evaluate the immune response against pneumococcal vaccines with regularity and accuracy. Keywords:Streptococcus pneumoniae, Antibodies, Enzyme-Linked Immunosorbent Assay, Validation Studies == Graphical Abstract == == Intro == Streptococcus pneumoniaeare encapsulated bacteria characterized by a polysaccharide (PS) capsule, which is a major virulence Fatostatin element (1).S. pneumoniaeis a predominant cause of many diseases, including meningitis, sepsis, pneumonia, and otitis press in young babies and the elderly (1,2). With the significant increase in multi-drug resistantS. pneumoniaeworldwide, many attempts have been made to promote prevention of the disease and development of effective vaccines. The 14-valent pneumococcal PS vaccine (PPSV) was licensed in 1977 (3) and thereafter, the 23-valent PPSV was developed in 1983. These vaccines induce T-cell-independent immune responses and are more effective in adults than in young children, who are the highest risk human population for pneumococcal illness (4). To induce immunity in young children, the 7-valent pneumococcal conjugate vaccine (PCV7) comprising serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F was developed. PCV7 was shown to be highly effective for the prevention of invasive pneumococcal disease in babies and children (5,6). The effectiveness of a vaccine is determined by the difference in the incidence of specific diseases among vaccinated and unvaccinated subjects for the disease. However, once a vaccine is definitely proven to be effective, effectiveness tests are no Rabbit Polyclonal to RAD17 longer honest or Fatostatin feasible to perform. Since safety against pneumococcal illness is definitely mediated by antibodies specific to the capsular PS serotype, an enzyme-linked immunosorbent assay (ELISA) that actions immunoglobulin G (IgG) levels is used in the evaluation of pneumococcal vaccines like a surrogate assay. The World Health Corporation (WHO) has offered a laboratory guideline for the ELISA to quantify IgG antibodies specific to pneumococcal PS (PnPS) since 2000 (7,8). In addition, the National Institute for Biological Requirements Control (NIBSC) in the UK put together 12 calibration serum samples with assigned antibody titers to assist laboratories working on the evaluation of pneumococcal vaccines (9). The goal of this study was to validate the WHO ELISA for the serotype-specific anti-pneumococcal IgG in the Ewha Center for Vaccine Evaluation and Study. The results were anticipated to serve as evidence of the capability and accuracy of the evaluation of pneumococcal vaccines at our center. == MATERIALS AND METHODS == == Materials == == Study design == This was a validation study of the WHO ELISA for the detection of the serotype-specific anti-pneumococcal IgG in the Ewha Center for Vaccine Evaluation and Study. == Study materials == The serum research assay standard, 89-SF, was from Dr. C. Frasch (Center for Biologics Evaluation and Study, Food and Drug Administration, Bethesda, MD, USA). The 7 serotype specific PS antigens (4, 6B, 9V, 14, 18C, 19F, and 23F) were purchased from your American Type Tradition Collection (ATCC, Rockville, MD, USA). Cell wall PS (C-PS) utilized for the removal of nonspecific reactivity was purchased from Statens Serum Institute, Copenhagen, Denmark. The PnPS 22F, which was selected for better absorption of the common nonspecific epitopes, was purchased from ATCC. For the test sera, 5 out of 12 Fatostatin pneumococcal ELISA calibration sera (748, 752, 754, 760, and 764, NIBSC, Hertfordshire, UK), which had been provisionally assigned for the detection of IgG concentrations for the 7 serotypes, were used. The serum research assay standard, 89-SF, was assigned as 4.1 g/mL for PnPS 4, 16.9 g/mL for PnPS 6B, 6.9 g/mL for PnPS 9V, 27.8 g/mL for PnPS 14, 4.5 g/mL for PnPS 18C, 13.0 g/mL for PnPS 19F, and 8.1 g/mL for PnPS 23F (7). 89-SF for each of the serotypes was prepared at a 1:1,000 dilution with absorption solutions including only C-PS. The calibration sera 748, 752, 754, 760, and 764 were prepared at 1:250 dilutions with absorption solutions with C-PS and PS type 22F. The diluted sera were used at 2.5-fold serial dilutions up to 7 times with dilution ranges from 1/250 to 1/24,414. Each PnPS was prepared at a concentration of 2 mg/mL and was stored at 20C. They were used in a concentration of a 5 g/mL Fatostatin with phosphate-buffered saline buffer (comprising both 0.02%.